Relmada Therapeutics Stock Price Prediction

RLMD Stock  USD 3.02  0.12  4.14%   
At the present time, the relative strength index (RSI) of Relmada Therapeutics' share price is approaching 34 indicating that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Relmada Therapeutics, making its price go up or down.

Oversold Vs Overbought

34

 
Oversold
 
Overbought
The successful prediction of Relmada Therapeutics' future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Relmada Therapeutics and does not consider all of the tangible or intangible factors available from Relmada Therapeutics' fundamental data. We analyze noise-free headlines and recent hype associated with Relmada Therapeutics, which may create opportunities for some arbitrage if properly timed. Below are the key fundamental drivers impacting Relmada Therapeutics' stock price prediction:
EPS Estimate Next Quarter
(0.62)
EPS Estimate Current Year
(1.98)
EPS Estimate Next Year
(1.64)
Wall Street Target Price
12
EPS Estimate Current Quarter
(0.64)
Using Relmada Therapeutics hype-based prediction, you can estimate the value of Relmada Therapeutics from the perspective of Relmada Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Relmada Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Relmada because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Relmada Therapeutics after-hype prediction price

    
  USD 2.94  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Relmada Therapeutics Basic Forecasting Models to cross-verify your projections.
For information on how to trade Relmada Stock refer to our How to Trade Relmada Stock guide.
Intrinsic
Valuation
LowRealHigh
0.744.748.74
Details
Naive
Forecast
LowNextHigh
0.063.207.20
Details
4 Analysts
Consensus
LowTargetHigh
9.4510.3811.52
Details
Earnings
Estimates (0)
LowProjected EPSHigh
0.000.000.00
Details

Relmada Therapeutics After-Hype Price Prediction Density Analysis

As far as predicting the price of Relmada Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Relmada Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Relmada Therapeutics, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Relmada Therapeutics Estimiated After-Hype Price Volatility

In the context of predicting Relmada Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Relmada Therapeutics' historical news coverage. Relmada Therapeutics' after-hype downside and upside margins for the prediction period are 0.15 and 6.94, respectively. We have considered Relmada Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
3.02
2.94
After-hype Price
6.94
Upside
Relmada Therapeutics is relatively risky at this time. Analysis and calculation of next after-hype price of Relmada Therapeutics is based on 3 months time horizon.

Relmada Therapeutics Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Relmada Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Relmada Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Relmada Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.23 
4.00
  0.08 
  0.08 
8 Events / Month
14 Events / Month
In about 8 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
3.02
2.94
2.65 
1,212  
Notes

Relmada Therapeutics Hype Timeline

Relmada Therapeutics is at this time traded for 3.02. The entity has historical hype elasticity of -0.08, and average elasticity to hype of competition of 0.08. Relmada is expected to decline in value after the next headline, with the price expected to drop to 2.94. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -2.65%, whereas the daily expected return is at this time at 0.23%. The volatility of related hype on Relmada Therapeutics is about 1208.79%, with the expected price after the next announcement by competition of 3.10. About 46.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.91. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Relmada Therapeutics recorded a loss per share of 2.86. The entity last dividend was issued on the 30th of September 2019. The firm had 1:4 split on the 30th of September 2019. Given the investment horizon of 90 days the next expected press release will be in about 8 days.
Check out Relmada Therapeutics Basic Forecasting Models to cross-verify your projections.
For information on how to trade Relmada Stock refer to our How to Trade Relmada Stock guide.

Relmada Therapeutics Related Hype Analysis

Having access to credible news sources related to Relmada Therapeutics' direct competition is more important than ever and may enhance your ability to predict Relmada Therapeutics' future price movements. Getting to know how Relmada Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Relmada Therapeutics may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
CYTKCytokinetics(0.83)10 per month 0.00 (0.08) 3.52 (4.15) 14.08 
DICEDice Molecules Holdings 0.02 7 per month 1.14  0.10  5.66 (2.91) 37.64 
EWTXEdgewise Therapeutics 1.60 10 per month 2.67  0.12  6.65 (4.64) 61.02 
KRTXKaruna Therapeutics 0.00 0 per month 1.67 (0.04) 3.38 (2.71) 10.01 
DYNDyne Therapeutics 1.29 10 per month 0.00 (0.10) 6.03 (5.63) 32.53 
THRDThird Harmonic Bio(0.28)7 per month 4.79  0.02  8.35 (6.74) 25.76 
PMVPPmv Pharmaceuticals(0.1)3 per month 1.99 (0.03) 3.75 (3.64) 13.98 
RVMDRevolution Medicines 1.10 9 per month 2.00  0.14  4.81 (3.24) 10.95 
PRDSPardes Biosciences 0.02 3 per month 1.66  0.09  4.28 (2.59) 15.31 
STTKShattuck Labs(0.01)10 per month 0.00 (0.17) 6.93 (9.82) 51.03 
ELYMEliem Therapeutics 0.25 4 per month 0.00 (0.19) 6.21 (9.35) 34.87 
CSBRChampions Oncology 0.34 6 per month 4.04 (0.01) 6.56 (7.11) 22.49 
IPSCCentury Therapeutics 0.07 9 per month 4.28  0.01  7.44 (6.82) 21.67 
FUSNFusion Pharmaceuticals 0.23 34 per month 3.26 (0.02) 7.92 (5.02) 23.08 
BCYCBicycle Therapeutics 0.15 10 per month 0.00 (0.04) 4.68 (3.70) 35.92 
RAPTRAPT Therapeutics 0.23 5 per month 0.00 (0.08) 10.00 (11.56) 61.07 
NAMSNewAmsterdam Pharma 3.09 28 per month 3.39  0.06  5.33 (4.57) 29.23 
CYTCyteir Therapeutics 0.09 2 per month 2.57  0.08  10.00 (5.26) 36.14 
NUVBNuvation Bio 0.21 8 per month 0.00 (0.04) 9.48 (8.36) 21.30 
MGTAMagenta Therapeutics(0.02)2 per month 3.40 (0) 5.88 (4.29) 16.99 
NLTXNeoleukin Therapeutics(0.14)1 per month 0.00 (0.08) 4.05 (3.53) 27.84 
GRPHGraphite Bio(0.03)1 per month 0.00 (0.08) 4.79 (4.73) 14.40 

Relmada Therapeutics Additional Predictive Modules

Most predictive techniques to examine Relmada price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Relmada using various technical indicators. When you analyze Relmada charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Relmada Therapeutics Predictive Indicators

The successful prediction of Relmada Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Relmada Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Relmada Therapeutics based on analysis of Relmada Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Relmada Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Relmada Therapeutics's related companies.
 2019 2021 2023 2024 (projected)
Payables Turnover4.5E-41.12E-41.29E-41.23E-4
Days Of Inventory On Hand87.9K3.3M3.0M3.1M

Story Coverage note for Relmada Therapeutics

The number of cover stories for Relmada Therapeutics depends on current market conditions and Relmada Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Relmada Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Relmada Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Relmada Therapeutics Short Properties

Relmada Therapeutics' future price predictability will typically decrease when Relmada Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Relmada Therapeutics often depends not only on the future outlook of the potential Relmada Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Relmada Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding30.1 M
Cash And Short Term Investments96.3 M

Complementary Tools for Relmada Stock analysis

When running Relmada Therapeutics' price analysis, check to measure Relmada Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relmada Therapeutics is operating at the current time. Most of Relmada Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relmada Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relmada Therapeutics' price. Additionally, you may evaluate how the addition of Relmada Therapeutics to your portfolios can decrease your overall portfolio volatility.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Global Correlations
Find global opportunities by holding instruments from different markets
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Commodity Directory
Find actively traded commodities issued by global exchanges
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges